MRM Health, a Ghent-based clinical-stage biopharmaceutical company developing microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million Series B financing round.
The round was led by French pharmaceutical group Biocodex and included participation from ATHOS, as well as new investor BNP Paribas Fortis Private Equity and existing investors SFPIM, Ackermans & van Haaren (AvH), OMX Europe Venture Fund (OMX), Qbic II and VIB.
“This funding marks a pivotal moment for MRM Health,” said Sam Possemiers, CEO of MRM Health. “With the support of our experienced international investor syndicate, we are now well positioned to deliver transformative therapies for patients with chronic inflammatory diseases, where current treatments often fall short. Our CORAL platform gives us a unique edge in designing potent, resilient and scalable microbiome-based therapeutics. This new funding will allow us to further build both our platform and pipeline.”
Founded in 2020, MRM Health is a biopharmaceutical company focused on the discovery and development of therapeutics based on the human microbiome. The company is based in a Center of Expertise for microbiome research and development in the BioTech cluster, and has a strategic partnership with the VIB.
MRM Health’s proprietary technology platform aims to bring live microbial therapeutics development to the next level by combining rationally selected strains into synergistic consortia through a proprietary optimisation process.
Its CORAL platform enables the design and manufacturing of disease-focused microbial consortia with enhanced efficacy and scalability.
“Biocodex is a pioneer in microbiota science for over 70 years,” said Nicolas Coudurier, CEO of Biocodex. “We are excited to support MRM Health’s unique platform approach and leadership role in the field, reflecting our strategy of fostering innovation rooted in our core expertise. By combining our long-standing leadership in microbiota with breakthrough live biotherapeutics platforms, we aim to deliver meaningful solutions for patients, worldwide.”
The proceeds raised will enable MRM Health to complete a Phase 2b clinical trial for its lead programme MH002 in patients suffering from mild-to-moderate ulcerative colitis. MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD), with positive clinical data in Phase 2a trials reportedly showing safety and initial efficacy in both mild-to-moderate ulcerative colitis and in the orphan disease indication pouchitis.
In addition, the company will advance two novel microbial consortia programmes to IND approval, targeting inflammation and improved efficacy of immune-oncology therapies, respectively.
MRM Health also plans to expand its portfolio of LBPs through strategic partnerships in both human and animal health.
“MRM Health is at the forefront of a new era in microbiome-based therapeutics,” said Julian Zachmann, from ATHOS. “Their technology has reached the maturity needed to effectively develop, scale and commercialise live biotherapeutics for major chronic inflammatory diseases with high unmet need. We are proud to support their journey toward significant patient impact.”
As part of the financing, MRM Health and Biocodex intend to enter a strategic collaboration to develop both novel therapeutic assets and scalable manufacturing capabilities for LBPs. This partnership will provide additional non-dilutive funding in the coming years, further strengthening the company’s operational foundation.
“BNP Paribas Fortis Private Equity is delighted to join a strong syndicate of investors to support the further development of MRM Health. With two decades of unique scientific expertise in the field of microbiome, this funding round reflects our confidence in MRM Health’s technology and the management’s ability to translate science into therapeutic solutions that will truly make a difference for patients,” said Raf Moons, Head of BNP Paribas Fortis Private Equity.
As part of the Series B financing, Jean-Patrick Hennebelle (Biocodex), Julian Zachmann (ATHOS) and Goedele Ertveldt (SFPIM) will join MRM Health’s Board of Directors.
“We warmly welcome our new investors and thank them for their trust,” said Werner Cautreels, Chairman of MRM Health Board of Directors. “With this strong international syndicate, MRM Health is well equipped to advance its pipeline and deliver this novel class of therapeutics to patients in need of alternative, innovative treatment options.”
Read the orginal article: https://www.eu-startups.com/2025/09/belgiums-mrm-health-raises-e55-million-for-microbiome-based-biotherapeutic-product-pipeline/
